In this issue:
Molecular MRD in AML
Ibrutinib plus venetoclax for MCL
Venetoclax plus rituximab in R/R CLL
R-CVP vs R-CHOP vs R-FM in follicular lymphoma
R-CHOP or CHOP plus 131I-tositumomab in follicular lymphoma
TP53 germline variations in paediatric ALL
Brentuximab vedotin plus nivolumab in R/R Hodgkin lymphoma
NOPHO ALL2008 treatment for patients with ALL
Ibrutinib, lenalidomide and rituximab in R/R MCL
5-year follow-up in MDS patients treated with romiplostim
Please login below to download this issue (PDF)